QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=1142ADF458CEAD4BB08E0B1EFB1C5BBA;jsessionid=FCC51A36F7440D07D66F3B58763DD2BE;jsessionid=1225A0A19E9BC5E974AB699BE863AAE4;jsessionid=39968F1ED7A1450139992629B35C7D79;jsessionid=FB7AD83C4D39F47319DC5C58EE454813;jsessionid=AB481D556545D458DE09FFC25F04BD05;jsessionid=1629BB9C70BF0A362928D9CF42A31A8C (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=C22459D1FC782BBF88AE726AB2ED8519;jsessionid=63DE3311F32126CEC93952F329EA64C4;jsessionid=1142ADF458CEAD4BB08E0B1EFB1C5BBA;jsessionid=FCC51A36F7440D07D66F3B58763DD2BE;jsessionid=1225A0A19E9BC5E974AB699BE863AAE4;jsessionid=39968F1ED7A1450139992629B35C7D79;jsessionid=FB7AD83C4D39F47319DC5C58EE454813;jsessionid=AB481D556545D458DE09FFC25F04BD05;jsessionid=1629BB9C70BF0A362928D9CF42A31A8C